Unicycive Therapeutics, Inc.

UNCY Nasdaq SEC CIK 1766140
Follow Unicycive Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$7M −16.4% vs same quarter last year
EPS, diluted −$0.25 +24.2% vs same quarter last year
Operating cash flow −$7.2M −21.6% vs same quarter last year
Operating income −$8.8M −20.4% vs same quarter last year
Net income by quarter
−$21.5M
$570K
−$6.4M
−$6M
−$14.7M
−$12.8M
−$1.7M
−$7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$40M−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$26.6M
FY24−$36.7M
FY23−$30.5M
FY22−$18.1M
FY21−$10M
FY20−$2.3M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$31.3M
FY24−$28.6M
FY23−$18.3M
FY22−$15.7M
FY21−$5.8M
FY20-
FY19-